Why Overrides Need Rules
A dosing recommendation is decision support, not an order that eliminates clinical judgment. A clinician may have relevant information that the model did not use, or may judge that the recommended action does not fit the patient’s current circumstances. But discretion without a defined process can quietly defeat dose limits, conceal system failures, or make later review impossible. A safe policy therefore specifies both when a recommendation may be changed and when the case must leave the routine pathway for review.
This tutorial assumes that the recommendation has passed the applicable input, plausibility, contraindication, uncertainty, and fallback checks. If the output is unusable, the appropriate fallback process applies; an override is not a way to make unusable output appear valid. Likewise, a clinician changing a suggested dose is not the same as authorizing an action that violates a hard safety constraint.
Separate the Recommendation From the Permitted Actions
A recommendation is one proposed action. The policy also defines which actions are allowed in the current pathway, including applicable dose bounds, rate limits, and required safety gates. A clinician may select a different action within that permitted set if the policy allows a routine override and the rationale is clinically sound. If the proposed action falls outside the permitted set, routine override authority is insufficient.
For a concise formal representation, let \(d_{\mathrm{rec}}\) be the model-recommended dose, let \(d_{\mathrm{prop}}\) be the dose the clinician proposes, and let \(\mathcal{A}_{\mathrm{permitted}}\) be the set of actions allowed by the active policy for this patient and decision. The first question is whether the proposed action is permitted, not whether the clinician can explain why it differs from the model.
This is a decision rule, not a claim that every action inside the permitted set is clinically appropriate. The clinician still needs a patient-specific rationale and must follow other applicable requirements. Conversely, a compelling rationale does not automatically make an out-of-policy action permissible. If policy permits a defined exception process, the case must use that process and receive the required authorization before implementation.
A Governed Override and Escalation Workflow
A usable workflow makes the decision sequence explicit. It should identify who may make a routine override, who reviews exceptions, what information must be recorded, and what to do while review is pending. The steps below describe a general structure; the approved local policy supplies the actual roles, time limits, and action permissions.
Confirm that the recommendation is usable and that required checks have been completed. If the output failed a check, use the specified fallback or safety process instead of labeling the action an override.
Record the action being considered and compare it with the applicable permitted range, rate limits, and other policy conditions. Do not infer permission from the fact that a clinician can enter the value into the system.
Identify the patient-specific fact or clinical judgment that supports departing from the recommendation, its source and timing, and why the proposed action is appropriate under the policy.
If the action is within the permitted set and the clinician is authorized, proceed only as the policy allows. If a required review condition is met, or information and judgments remain in conflict, route the case to the designated reviewer.
Document whether the proposed action was implemented, revised, deferred, or declined; who made or reviewed the decision; and the reason. Make clear when review is pending so a proposal is not mistaken for an authorized action.
What the Record Must Explain
Documentation should allow another qualified person to reconstruct the decision without guessing what “clinical judgment” meant. A useful record links the recommendation, the proposed action, the reason for the difference, and the authority under which the final action was taken. It should be concise enough to use at the point of care but specific enough to support handoff and review.
- Recommendation and proposed action: state both values, units, and the relevant dosing schedule; do not record only “overridden.”
- Reason for departure: identify the patient-specific circumstance or clinical judgment, not a generic phrase such as “not appropriate.”
- Evidence and timing: note the source and time of relevant information, such as a confirmed clinical observation or a documented change in context.
- Constraint check: record whether the proposed action meets applicable bounds, rate limits, and required gates, or identify the exception review required.
- Decision-maker and review: identify the responsible clinician, any required reviewer, and the resulting disposition.
- Communication: record who was informed when another clinician, service, or patient needs to know the decision.
Documentation should describe the rationale actually used, not manufacture a justification after the fact. It should also distinguish a clinician’s observation from a model output and avoid implying that a value was verified if it was not. These details matter for continuity of care, accountability, and later evaluation of whether the policy is functioning as intended.
Worked Example: A Within-Policy Override
Hypothetical policy and case. For this decision pathway, doses must be between 60 mg and 100 mg, inclusive, and a dose change may not exceed 20 mg at one decision. A usable recommendation is 60 mg. All required safety gates have passed. The clinician proposes 75 mg because a recent, confirmed patient-specific measurement, not represented in the model inputs, supports a modest increase. The clinician is authorized to make within-range decisions.
First, compare the proposed action with the dose bounds: \(60 \leq 75 \leq 100\) mg. Next, calculate the size of the change from the recommendation: \(75-60=15\) mg. Since \(15 \leq 20\) mg, the proposal also meets the stated rate limit. These checks establish policy eligibility for a routine override; they do not independently prove that 75 mg is the right clinical action.
The clinician records the 60 mg recommendation, the proposed 75 mg dose, the confirmed measurement and its timing, why it supports departing from the recommendation, and that the bounds and rate limit were checked. The clinician then records the final decision and any required communication. Under the hypothetical policy, no additional escalation criterion is stated, so a routine override may proceed. If the local policy required review for this type of rationale, that rule would take precedence.
Worked Example: Proposed Dose Below the Pathway Minimum
Hypothetical policy and case. The permitted range for this pathway is 60–100 mg. A usable model recommendation is 70 mg, but the clinician proposes 55 mg because a new clinical concern may make the routine dose unsuitable. The policy states that any proposed action below 60 mg requires review by the designated specialist before implementation.
The proposed action is below the pathway minimum: \(55<60\) mg. The fact that the clinician has a reason to consider 55 mg does not make it a routine within-policy override. The clinician documents the recommendation, the 55 mg proposal, the new concern and its source, and the fact that the proposal falls below the permitted minimum.
The case is escalated to the designated specialist. The 55 mg proposal is not implemented while that review is pending, because the stated policy requires review before implementation. The specialist’s disposition must be recorded. If the policy does not authorize an exception after review, the specialist cannot simply waive the bound; the case must remain within permitted actions or follow another formally authorized pathway. This is a boundary case, not an example of a routine override.
When Escalation Is Required
Escalation criteria should be stated before a difficult case occurs. They commonly include conditions such as the following, when specified by the applicable policy:
- The proposed action is outside a dose bound or rate limit, or would otherwise cross a hard safety constraint.
- A required safety gate fails, or a contraindication or other critical concern is identified. The appropriate response may be a stop or an urgent pathway, not merely routine review.
- Important clinical information is conflicting, cannot be verified, or makes the recommendation’s applicability uncertain.
- The case meets a defined high-risk or exception criterion, or the clinician is uncertain whether the action is within their authority.
- Two responsible clinicians disagree about the action and the disagreement cannot be resolved under the local process.
Escalation is not a substitute for immediate action required by an urgent safety protocol. Local policy should specify what can safely happen while review is pending, who receives the escalation, and how urgent cases are routed. An escalation must produce a disposition: for example, authorize an action under an explicit exception, select an in-policy action, obtain more information, or decline the proposal. A message sent without an identified recipient or follow-up path is not a complete escalation process.
Worked Example: Conflicting Clinical Judgments
Worked Example: Conflict About a Permitted Dose
Hypothetical policy and case. A usable recommendation is 80 mg. The permitted range is 60–100 mg, and the maximum change from the recommendation is 20 mg. One clinician proposes 70 mg based on a documented patient-specific concern; a second clinician believes the concern does not justify departing from 80 mg. Both proposed doses meet the numerical limits: \(60 \leq 70 \leq 100\) mg and \(|70-80|=10 \leq 20\) mg.
Passing the numeric checks does not resolve the disagreement. The policy for this hypothetical pathway requires unresolved disagreement between responsible clinicians to be reviewed by the designated service. The clinicians record the recommendation, both proposed judgments, the evidence and rationale each relies on, and the unresolved point. They escalate rather than treating the first proposal as approved merely because it is within range.
The designated reviewer’s decision is recorded with the responsible person and disposition. Until that decision is made, the team follows the local policy for pending review; it does not assume that either proposal has been authorized. The example illustrates why escalation rules must cover uncertainty and conflict as well as numeric boundary violations.
Comparison, Diagnostics, and Limitations
| Situation | Appropriate route | What must not be assumed |
|---|---|---|
| Usable recommendation; proposed action is permitted; authorized clinician has a documented rationale | Routine override, if local policy allows | That a within-range action is automatically clinically appropriate |
| Proposed action crosses a stated bound or requires an exception | Mandatory review or formally authorized exception pathway | That a persuasive rationale alone waives the constraint |
| Model output is unusable | Specified fallback process | That changing the output converts it into a usable recommendation |
| Critical safety concern or unresolved conflict | Safety response or designated escalation, as policy specifies | That routine discretion is sufficient to settle the case |
Operational warning signs include overrides with no stated reason, repeated use of generic documentation, proposed actions outside bounds being implemented before review, missing reviewer dispositions, and inconsistent routing of similar cases. These are signals to examine the workflow, not proof by themselves that a particular clinical decision was wrong. Review should ask whether staff could find the applicable rule, whether the rule was followed, and whether the recorded rationale matches the information available at the time.
A governance rule cannot replace clinical judgment or guarantee a correct outcome. Poorly specified authority can produce either unsafe latitude or excessive escalation; vague criteria can make similar cases receive different treatment. The rules also depend on current, accurate information and a clear assignment of responsibility. Local clinical governance must define the actual bounds, authorized roles, exception conditions, urgency routes, and record-retention requirements.
Common Mistake
Wrong reasoning: “The clinician knows the patient, so any different dose can be entered as an override.” This confuses professional judgment with authority to bypass a defined safety constraint. It also leaves no reliable way to distinguish a justified in-policy decision from an unreviewed exception.
Correction: First establish whether the output is usable, then check the proposed action against the active policy and confirm the clinician’s authority. Document the patient-specific rationale. If a required escalation condition is present, route the case and wait for the specified disposition before taking an action that policy does not yet authorize.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions.
- A usable recommendation is 80 mg. The proposed dose is 95 mg, the permitted range is 60–100 mg, and the maximum change is 20 mg. Does it pass these numeric checks, and what else is required for a routine override?
- A policy requires specialist review before any action below 60 mg. The clinician proposes 55 mg with a documented rationale. May the clinician implement it immediately?
- Name four elements that make an override record reviewable.
- A recommendation is unusable because a required check failed. Is changing its dose value a clinician override under the workflow described here? What route applies?
- Two clinicians disagree about a proposed in-range action, and policy requires review for unresolved disagreement. What should be documented and done?
Solutions. (1) The change is \(95-80=15\) mg, and \(60 \leq 95 \leq 100\) mg, so both numeric checks pass. A routine override still requires an authorized clinician, a patient-specific rationale, any required safety gates, and the documentation and approval specified by policy. (2) No. Since \(55<60\) mg and review is required before implementation, the proposal must be escalated and must not be implemented while review is pending. (3) Examples include the model recommendation and proposed action with units, the patient-specific rationale, the source and timing of relevant evidence, the constraint check, the decision-maker and reviewer, and the final disposition. Any four of these are acceptable. (4) No. A failed required check makes the output ineligible for this override workflow; use the specified fallback or safety process. (5) Record the recommendation, each clinician’s proposed judgment and rationale, the evidence each relies on, and the unresolved disagreement. Escalate to the designated reviewer and follow the local pending-review process rather than assuming either proposal is authorized.